HPV TESTING MARKET SIZE TO CROSS USD 1.1 BILLION BY 2025, GROWING AT A CAGR OF 12% DURING THE FORECAST PERIOD

HPV Testing Market Analysis Report by Products (Consumables, Instruments), Applications (Cervical Cancers, Vaginal Cancers, Others), End-user (Standard Reference Laboratories, Hospitals, Physicians’ Office and Clinics), and Geography (North America, Europe, APAC, Latin America, and Middle East & Africa), Market size, Share, Price Trends, Competitive Analysis, Growth and Forecast 2020-2025

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

236 Pages

icon-table

42 Tables

icon-chart

149 Charts

icon-region

5 Regions

icon-country

18 Countries

icon-company

20 Companies

icon-market

4 Market Segment

HPV TESTING MARKET REPORT SCOPE

Report Attribute Details
Market Size (REVENUE) USD 1.1 BILLION (2025)
CAGR 12% (2020 - 2025)
Base Year 2019
Forecast Year 2020-2025
Market Segments Products (Consumables, Instruments), Applications (Cervical Cancers, Vaginal Cancers, Others), End-user (Standard Reference Laboratories, Hospitals, Physicians’ Office and Clinics)
Geographic Analysis North America, Europe, APAC, Latin America, and Middle East & Africa
Countries Covered US, Canada, Germany, France, UK, Spain, Italy, Japan, China, India, Australia, South Korea, Brazil, Mexico, Argentina, Turkey, Saudi Arabia, and South Africa

INDUSTRY INSIGHTS

The HPV testing market size to cross USD 1.1 billion by 2025, growing at a CAGR of 12% during the forecast period. The increased procurement of the latest generation HPV testing analyzers and test kits, coupled with the high prevalence of HPV infections and cancers, especially cervical and vaginal, influences the growth of the global HPV testing market. Traditionally, cervical cancer screening was based on cervical cytology or pap test. However, in recent years, several countries and global health bodies have recommended the inclusion of HPV tests for cervical and pre-cancer screening programs, which is likely to boost the market.

The demand for new innovative testing consumables and instruments using advanced techniques such as the HPV mRNA test, which promotes accurate and sensitive diagnostic outcomes, is driving the market growth. Further, with the availability of positive clinical evidence, demonstrating the superiority of the latest generation advanced testing devices, end-users will become increasingly aware of clinical benefits and rapidly adopt these tests as an essential screening tool for cervical cancer screening. Therefore, the improvement in patient management, favorable government initiatives for primary screening, and the rising awareness of advanced testing in developed and developing economies are increasing the adoption globally.

SNIPPETS

  • Approximately 570,000 cases of human papillomavirus cervical cancer cases are diagnosed annually across the globe. Cervical cancer in the US is the third most common disease among women, with over 14,065 new cases reported every year.
  • About 85% of diagnosed cervical cancers and related deaths occur among women living in lower-middle-income countries. China and India have the highest numbers of people with cervical cancers.
  • The growing awareness related to HPV testing for cervical cancer screening is contributing to the uptake of instruments and consumables.
  • Vendors need to focus on the development of mRNA HPV testing for high sensitivity and accuracy.

HPV TESTING MARKET SEGMENTATION 

This research report includes detailed segmentation by

  • Products
  • Applications
  • End-user
  • Geography

INSIGHTS BY PRODUCTS

The consumables segment is growing due to the high adoption of advanced testing kits, reagents, and other related consumables to detect and screen cervical cancers globally. The segment is also growing at a fast rate due to the recurring purchase by end-users to perform HPV tests. These screening tests are likely to gain wide acceptance in emerging economies. The growth is due to favorable government initiatives and the rise in consumer spending power. Therefore, market players are focusing on significant product launches in a low resource setting of emerging countries, thereby boosting the segment growth.

The instruments segment is growing at a slow pace as the procurement of analyzers is capital intensive and the purchasing decision depends on financial resources and budget allocations. However, the increasing availability of automated and compact analyzers/instruments has significantly improved the efficiency and quality of end-user operations. Automation and integration of several diagnostic platforms have led to the introduction of innovative diagnostic analyzers. This is driving the growth of the segment during the forecast period.

INSIGHTS BY APPLICATION

The cervical cancer application segment accounted for 80% market share of the global HPV testing market. The cervical application segment is growing on account of the rise in cervical cancer incidences. The launch of screening products in low resource countries is expected to drive the cervical application segment during the upcoming years. In the US region, HPV self-sampling is emerging as a potential cancer screening strategy. This is likely to contribute to market growth.

The application of HPV testing for vaginal cancer offers powerful negative predictive values. Therefore, the detection of infection with a high-risk HPV, which produce visible signs, is a powerful tool for vaginal cancer screening. The benefit of HPV testing, rising vaginal cancer, and innovative testing devices are driving the growth of the vaginal application segment.

INSIGHTS BY END-USERS    

In 2019, the standard reference laboratories segment accounted for 40% of the global HPV testing market. The standard reference laboratories help in improving overall diagnostic outcomes.

Healthcare professionals in hospitals use HPV testing as a screening procedure for cervical and other related cancers. The hospital segment is likely to grow at the fastest CAGR during the forecast period. A majority of patients with high-risk symptoms prefer visiting hospitals for diagnosis due to advanced infrastructure facilities.

The physicians’ office and clinic segment is expected to grow mainly on account of the growing prevalence of cervical cancers worldwide. The market is growing at a healthy rate with 12% CAGR during the forecast period. Another factor responsible for the rise of this segment is the availability of super-specialty expertise in these clinics.

INSIGHTS BY GEOGRAPHY

North America is growing at a healthy rate and this trend is likely to continue during the forecast period. The growth is due to the growing preference for HPV tests to detect and screen cervical cancers and other related infections. The United States region is the major revenue contributor to the North America HPV testing market. The region accounted for a share of 95% in 2019.

The HPV testing market share in Europe is the second-largest and accounted for a 24% share in 2019. Germany, France, the UK, Spain, and Italy are the leading contributors to the Europe region.

The APAC region has the highest population with a high risk of developing cervical cancers and other associated infections. Japan, China, Australia, South Korea, and India are the major revenue contributors from the region. Japan is the major revenue contributor to the HPV testing market in APAC. The growth is due to advancements in healthcare infrastructure, the rise in healthcare expenditure, and favorable public and private initiatives for an increase in healthcare access.

INSIGHTS BY VENDORS

The global HPV testing market share is highly competitive and characterized by the presence of several global, regional, and local players. F. Hoffmann-La Roche, QIAGEN, Hologic, and Abbott Laboratories are the dominant players. Their testing instruments and consumables are widely used by end-users globally. These companies have a wide geographic footprint, diversified product portfolio, and a strong focus on innovation and research activities. Over the years, these players have been dominating the market as they have introduced safe and efficient products in the market.

The global HPV testing market research report includes in-depth coverage of the industry analysis with revenue, growth trends, and forecast insights for the following segments:

Market Segmentation by Products  

  • Consumables
  • Instruments

By Applications  

  • Cervical Cancers
  • Vaginal Cancers
  • Others

By End-user   

  • Standard Reference Laboratories
  • Hospitals
  • Physicians’ Office and Clinics

By Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
  • APAC
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Turkey
    • South Africa
    • Saudi Arabia

Frequently Asked Questions

What is the HPV testing market size and growth forecast?

The size is expected to reach revenues of $1.1 billion, growing at a CAGR of 12% during 2019-2025.

What are the factors impacting the growth of the market?

The demand for new innovative testing consumables and instruments using advanced techniques such as the HPV mRNA test, which promotes accurate and sensitive diagnostic outcomes, is driving the market growth.

Who are the key players in the HPV testing market?

The leading players are Hoffmann-La Roche, QIAGEN, Hologic, and Abbott.

Which segment is contributing to the HPV testing market growth?

The demand for new innovative testing consumables and instruments using advanced techniques such as the HPV mRNA test, which promotes accurate and sensitive diagnostic outcomes, is driving the market growth.

Download Free Sample

The global HPV testing market is expected to grow at a CAGR of over 12% during the period 2019–2025.

 The following factors are likely to contribute to the growth of the HPV testing market during the forecast period:

  • Increasing Prevalence of HPV Infections
  • Emergence of Point-of-care Diagnostics/Rapid HPV Tests
  • Rise of mRNA Test for Cervical Cancer Screening
  • Increasing Demand for HPV Co-testing

 Base Year:                  2019

Forecast Year:           2020–2025

The study considers the present scenario of the HPV testing market and its market dynamics for the period 2019−2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The study offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent companies operating in the market.

Key Vendors

  • Hoffmann-La Roche
    • Business Overview
    • Major Product Offerings
    • Key Strengths
    • Key Strategies
    • Key Opportunities
  • QIAGEN
  • Hologic
  • Abbott

 Other Vendors

  • Arbor Vita
    • Business Overview
    • Product Offerings
  • BD
  • Cepheid
  • DAAN Gene
  • DiaCarta
  • Fujirebio
  • Greiner Bio One International
  • Hybribio
  • IncellDx
  • Norgen Biotek
  • PreTect
  • Seegene
  • Siemens Healthineers
  • Takara Bio
  • Xiamen Zeesan Biotech
  • ZYTOVISION

Market Segmentation by Products  

  • Consumables
  • Instruments

Market Segmentation by Applications  

  • Cervical Cancers
  • Vaginal Cancers
  • Others

Market Segmentation by End-user   

  • Standard Reference Laboratories
  • Hospitals
  • Physicians’ Office and Clinics

Market Segmentation by Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
  • APAC
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Turkey
    • South Africa
    • Saudi Arabia

1 Research Methodology

2 Research Objectives

3 Research Process

4 Scope & Coverage

4.1 Market Definition

4.1.1 Inclusions

4.1.2 Exclusions

4.2 Base Year

4.3 Scope of the study

4.4 Market Segments

4.4.1 Market Segmentation by Product

4.4.2 Market Segmentation by Application

4.4.3 Market Segmentation by End-users

4.4.4 Market Segmentation by Geography

5 Report Assumptions & Caveats

5.1 Key Caveats

5.2 Currency Conversion

5.3 Market Derivation

6 Market at a Glance

7 Introduction

7.1 HPV Infections: An Overview

7.1.1 Background

7.1.2 Types of Human Papillomavirus

7.1.3 Cervical Cancer

7.1.4 Human Papillomavirus Tests

7.1.5 HPV Testing: Market Snapshot

8 Market Dynamics

8.1 Market Growth Enablers

8.1.1 Increasing Prevalence of Human Papillomavirus Infections

8.1.2 Growing Awareness & Favorable Guidelines Endorsing HPV Testing

8.1.3 High Demand for Nucleic Acid Amplification Tests

8.2 Market Growth Restraints

8.2.1 Availability of Alternative Diagnostic Methods for HPV

8.2.2 Increasing Focus on Preventive Measures for Human Papillomavirus Infections

8.2.3 Lower than Expected Market Penetration of HPV Tests

8.3 Market Opportunities and Trends

8.3.1 Emergence of Point-of-care/Rapid Human Papillomavirus Tests

8.3.2 High Growth Potential for HPV Tests in Low Resource Settings of LMICs

8.3.3 Emergence of mRNA Test for Cervical Cancer Screening

8.3.4 Increasing Demand for Human Papillomavirus Co-testing

9 Global HPV Testing Market

9.1 Market Overview

9.2 Market Size & Forecast

9.2.1 By Geography

9.2.2 By Product

9.2.3 By Application

9.2.4 By End-users

9.3 Five Forces Analysis

9.3.1 Threat of New Entrants

9.3.2 Bargaining Power of Suppliers

9.3.3 Bargaining Power of Buyers

9.3.4 Threat of Substitutes

9.3.5 Competitive Rivalry

10 HPV Testing Market by Product

10.1 Market Snapshot & Growth Engine

10.2 Market Overview

10.3 Consumables

10.3.1 Market Overview

10.3.2 Market Size & Forecast

10.4 Instruments

10.4.1 Market Overview

10.4.2 Market Size & Forecast

11 HPV Testing Market by Application

11.1 Market Snapshot & Growth Engine

11.2 Market Overview

11.3 Cervical Cancer

11.3.1 Market Overview

11.3.2 Market Size & Forecast

11.4 Vaginal Cancer

11.4.1 Market Overview

11.4.2 Market Size & Forecast

11.5 Others

11.5.1 Market Overview

11.5.2 Market Size & Forecast

12 HPV Testing Market by End-Users

12.1 Market Snapshot & Growth Engine

12.2 Market Overview

12.3 Standard Reference Laboratories

12.3.1 Market Overview

12.3.2 Market Size & Forecast

12.4 Hospitals

12.4.1 Market Overview

12.4.2 Market Size & Forecast

12.5 Physicians’ Offices and Clinics

12.5.1 Market Overview

12.5.2 Market Size & Forecast

13 HPV Testing Market by Geography

13.1 Market Snapshot & Growth Engine

13.2 Overview

14 North America

14.1 Market Overview

14.2 Market Size & Forecast

14.3 HPV Testing Market Segmentation by Product

14.4 Key Countries

14.4.1 US: Market Size & Forecast

14.4.2 Canada: Market Size & Forecast

15 Europe

15.1 Market Overview

15.2 Market Size & Forecast

15.3 Key Countries

15.4 HPV Testing Market Segmentation by Product

15.4.1 UK: Market Size & Forecast

15.4.2 France: Market Size & Forecast

15.4.3 Germany: Market Size & Forecast

15.4.4 Italy: Market Size & Forecast

15.4.5 Spain: Market Size & Forecast

16 APAC

16.1 Market Overview

16.2 Market Size & Forecast

16.3 HPV Testing Market Segmentation by Product

16.4 Key Countries

16.4.1 Japan: Market Size & Forecast

16.4.2 China: Market Size & Forecast

16.4.3 Australia: Market Size & Forecast

16.4.4 South Korea: Market Size & Forecast

16.4.5 India: Market Size & Forecast

17 Latin America

17.1 Market Overview

17.2 Market Size & Forecast

17.3 HPV Testing Market Segmentation by Product

17.4 Key Countries

17.4.1 Brazil: Market Size & Forecast

17.4.2 Mexico: Market Size & Forecast

17.4.3 Argentina: Market Size & Forecast

18 Middle East & Africa

18.1 Market Overview

18.2 Market Size & Forecast

18.3 HPV Testing Market Segmentation by Product

18.4 Key Countries

18.4.1 Turkey: Market Size & Forecast

18.4.2 South Africa: Market Size & Forecast

18.4.3 Saudi Arabia: Market Size & Forecast

19 Competitive Landscape

19.1 Competition Overview

19.2 Market Share Analysis

19.2.1 F. Hoffmann-La Roche

19.2.2 QIAGEN

19.2.3 Hologic

19.2.4 Abbott

20 Key Vendors

20.1 F. Hoffmann-La Roche

20.1.1 Business Overview

20.1.2 Major Product Offerings

20.1.3 Key Strengths

20.1.4 Key Strategies

20.1.5 Key Opportunities

20.2 QIAGEN

20.2.1 Business Overview

20.2.2 Major Product Offerings

20.2.3 Key Strengths

20.2.4 Key Strategies

20.2.5 Key Opportunities

20.3 Hologic

20.3.1 Business Overview

20.3.2 Major Product Offerings

20.3.3 Key Strengths

20.3.4 Key Strategies

20.3.5 Key Opportunities

20.4 Abbott

20.4.1 Business Overview

20.4.2 Major Product Offerings

20.4.3 Key Strengths

20.4.4 Key Strategies

20.4.5 Key Opportunities

21 Other Prominent Vendors

21.1 Arbor Vita

21.1.1 Business Overview

21.1.2 Major Product Offerings

21.2 BD

21.2.1 Business Overview

21.2.2 Major Product Offerings

21.3 Cepheid

21.3.1 Business Overview

21.3.2 Major Product Offerings

21.4 DAAN Gene

21.4.1 Business Overview

21.4.2 Major Product Offerings

21.5 DiaCarta

21.5.1 Business Overview

21.5.2 Major Product Offerings

21.6 Fujirebio

21.6.1 Business Overview

21.6.2 Major Product Offerings

21.7 Greiner Bio-One International

21.7.1 Business Overview

21.7.2 Major Product Offerings

21.8 Hybribio

21.8.1 Business Overview

21.8.2 Major Product Offerings

21.9 IncellDx

21.9.1 Business Overview

21.9.2 Major Product Offerings

21.10 Norgen Biotek

21.10.1 Business Overview

21.10.2 Major Product Offerings

21.11 PreTect

21.11.1 Business Overview

21.11.2 Major Product Offerings

21.12 Seegene

21.12.1 Business Overview

21.12.2 Major Product Offerings

21.13 Siemens Healthineers

21.13.1 Business Overview

21.13.2 Major Product Offerings

21.14 Takara Bio

21.14.1 Business Overview

21.14.2 Major Product Offerings

21.15 Xiamen Zeesan Biotech

21.15.1 Business Overview

21.15.2 Major Product Offerings

21.16 Zytovision

21.16.1 Business Overview

21.16.2 Major Product Offerings

22 Report Summary

22.1 Key Takeaways

22.2 Strategic Recommendations

22.3 Quantitative Summary

22.3.1 By Product

22.3.2 By Application

22.3.3 By End-users

22.3.4 By Geography

23 Appendix

23.1 Abbreviations

List of Exhibits 

Exhibit 1               Segmentation of Global HPV Testing Market

Exhibit 2               Market Size Calculation Approach 2019

Exhibit 3               Symptoms of HPV

Exhibit 4               Different Types of Human Papillomavirus Based on Risk

Exhibit 5               Symptoms of Advanced Cervical Cancer

Exhibit 6               Major Market Dynamics in Global HPV Testing Market

Exhibit 7               Global HPV Testing Market by Geography 2019 (%)

Exhibit 8               Global HPV Testing Market by Product 2019 (%)

Exhibit 9               Impact of Increasing Prevalence of Human Papillomavirus Infections

Exhibit 10             Cervical Cancer Incidence & Mortality Rate

Exhibit 11             Worldwide Prevalence of Human Papillomavirus Types

Exhibit 12             Impact of Growing Awareness & Favorable Guidelines Endorsing Human Papillomavirus Testing

Exhibit 13             Updated Screening Guidelines for Cervical Cancer by US Preventive Services Task Force for Women in the Age Range of 30-65 Years in August 2018

Exhibit 14             Impact of High Demand for Nucleic Acid Amplification Tests

Exhibit 15             Scenarios where HPV DNA Test is Recommended

Exhibit 16             Impact of Availability of Alternative Diagnostic Methods for Human Papillomavirus

Exhibit 17             Key Advantages of Pap Tests

Exhibit 18             Key Advantages of VIA

Exhibit 19             Impact of Increasing Focus on Preventive Measures for Human Papillomavirus Infections

Exhibit 20             Impact of HPV Vaccination on HPV Infections in Various Age Groups

Exhibit 21             Impact of Lower than Expected Market Penetration of Human Papillomavirus Tests

Exhibit 22             Key Factors Hindering the Expected Market Penetration of HPV Testing in Developing Countries

Exhibit 23             Impact of Emergence of Point-of-care/Rapid Human Papillomavirus Tests

Exhibit 24             Impact of High Growth Potential for Human Papillomavirus Tests in Low Resource Settings of LMICs

Exhibit 25             Top 10 Countries with Highest Cervical Cancer Rate in 2018

Exhibit 26             Comparison of Cervical Cancer Mortality Rates in Less Developed and Developed Countries by Age Groups

Exhibit 27             Impact of Emergence of mRNA Test for Cervical Cancer Screening

Exhibit 28             The Most Important Advantages of mRNA Human Papillomavirus Test

Exhibit 29             Impact of Increasing Demand for HPV Co-testing

Exhibit 30             Use of Human Papillomavirus DNA Testing as an Adjunct to Cytology for Cervical Cancer Screening  in Women 30 Years and Older

Exhibit 31             Global HPV Testing Market 2019−2025 ($ million)

Exhibit 32             Global HPV Testing Market by Geography

Exhibit 33             Global HPV Testing Market by Product

Exhibit 34             Global HPV Testing Market by Application

Exhibit 35             Global HPV Testing Market by End-users

Exhibit 36             Five Force Analysis 2019

Exhibit 37             Incremental Growth by Product 2019-2025

Exhibit 38             Global Market by Product

Exhibit 39             Global Market Lifecycle by Product

Exhibit 40             Global Market by Product: Incremental Growth

Exhibit 41             Global Market by Product: Absolute Growth

Exhibit 42             Global Market by Product 2019−2025 ($ million)

Exhibit 43             Global Market by Product 2019−2025 (%)

Exhibit 44             Global Market by Consumables: Absolute & Incremental Growth

Exhibit 45             High-risk HPV-induced Cancers

Exhibit 46             Human Papillomavirus Testing Equipment Market 2019−2025 ($ million)

Exhibit 47             Global HPV Testing Market by Instruments: Absolute & Incremental Growth

Exhibit 48             Human Papillomavirus Testing Instruments Market 2019−2025 ($ million)

Exhibit 49             Incremental Growth by Application 2019-2025

Exhibit 50             Global Market by Application

Exhibit 51             Global Market Lifecycle by Application

Exhibit 52             Global Market by Application: Incremental Growth

Exhibit 53             Global Market by Application: Absolute Growth

Exhibit 54             Countries with Highest Cervical Cancer Rate in 2018

Exhibit 55             Potential Uses of HPV Testing

Exhibit 56             Human Papillomavirus Testing Market by Cervical Cancer: Absolute & Incremental Growth

Exhibit 57             Global Market by Cervical Cancer 2019−2025 ($ million)

Exhibit 58             Global Vaginal Cancer Incidence 2018

Exhibit 59             Global Market by Vaginal Cancer: Absolute & Incremental Growth

Exhibit 60             HPV Genotype Distribution in Vaginal Cancer Cases (%)

Exhibit 61             Global Market by Vaginal Cancer 2019−2025 ($ million)

Exhibit 62             Global Market by Other Cancers: Absolute & Incremental Growth

Exhibit 63             Global Oropharyngeal Cancer Incidence 2018

Exhibit 64             Global Vulvar Cancer Incidence 2018

Exhibit 65             Global Anal Cancer Incidence 2018

Exhibit 66             Global Penile Cancer Incidence 2018

Exhibit 67             Global HPV Testing Market by Others 2019−2025 ($ million)

Exhibit 68             Incremental Growth by End-users 2019-2025

Exhibit 69             Global Market by End-users

Exhibit 70             Global Market Lifecycle by End-users

Exhibit 71             Global Market by End-users: Absolute Growth

Exhibit 72             Global Market by End-users: Incremental Growth

Exhibit 73             Global Market by Standard Reference Laboratories: Absolute & Incremental Growth

Exhibit 74             Key Offerings by WHO LabNet for Standard Reference Laboratories

Exhibit 75             Global Market by Standard Reference Laboratories 2019−2025 ($ million)

Exhibit 76             Global Market by Hospitals: Absolute & Incremental Growth

Exhibit 77             Global Market by Hospitals 2019−2025 ($ million)

Exhibit 78             Global Market by Physicians’ Offices and Clinics: Absolute & Incremental Growth

Exhibit 79             Global Market by Physicians’ Offices and Clinics 2019−2025 ($ million)

Exhibit 80             Incremental Growth by Geography 2019-2025

Exhibit 81             Global Market by Geography

Exhibit 82             Global Market Lifecycle by Region

Exhibit 83             Global Market by Geography 2019

Exhibit 84             Global Market by Geography: Absolute Growth

Exhibit 85             Global Market by Geography: Incremental Growth

Exhibit 86             Human Papillomavirus Testing Market in North America

Exhibit 87             North America HPV Testing Market: Absolute & Incremental Growth

Exhibit 88             Market in North America 2019−2025 ($ million)

Exhibit 89             North America: Market by Product 2019 & 2025 (%)

Exhibit 90             North America: Market by Product 2019−2025 ($ million)

Exhibit 91             North America: Market by Product 2019−2025 (%)

Exhibit 92             Incremental Growth in North America 2019−2025

Exhibit 93             Market in US 2019−2025 ($ million)

Exhibit 94             Market in Canada 2019−2025 ($ million)

Exhibit 95             Europe HPV Testing Market 2019

Exhibit 96             Europe Market: Absolute & Incremental Growth

Exhibit 97             Market in Europe 2019–2025 ($ million)

Exhibit 98             Incremental Growth in Europe 2019-2025

Exhibit 99             Europe: Market by Product 2019−2025 ($ million)

Exhibit 100          Europe: Market by Product 2019−2025 (%)

Exhibit 101          Market in UK 2019−2025 ($ million)

Exhibit 102          The YPA Program Mainly Includes

Exhibit 103          Market in France 2019–2025 ($ million)

Exhibit 104          Market in Germany 2019–2025 ($ million)

Exhibit 105          Market in Italy 2019–2025 ($ million)

Exhibit 106          Market in Spain 2019–2025 ($ million)

Exhibit 107          APAC HPV Testing Market 2019

Exhibit 108          APAC Market: Absolute & Incremental Growth

Exhibit 109          Market in APAC 2019–2025 ($ million)

Exhibit 110          APAC: Market by Product 2019−2025 ($ million)

Exhibit 111          APAC: Market by Product 2019−2025 (%)

Exhibit 112          Incremental Growth in APAC 2019-2025

Exhibit 113          Market in Japan 2019–2025 ($ million)

Exhibit 114          Market in China 2019–2025 ($ million)

Exhibit 115          Market in Australia 2019–2025 ($ million)

Exhibit 116          Market in South Korea 2019–2025 ($ million)

Exhibit 117          Market in India 2019–2025 ($ million)

Exhibit 118          Latin America HPV Testing Market 2019

Exhibit 119          Latin America Market: Absolute & Incremental Growth

Exhibit 120          Market in Latin America 2019–2025 ($ million)

Exhibit 121          Latin America: Market by Product 2019−2025 ($ million)

Exhibit 122          Latin America: Market by Product 2019−2025 (%)

Exhibit 123          Incremental Growth in Latin America 2019-2025

Exhibit 124          Market in Brazil 2019–2025 ($ million)

Exhibit 125          Market in Mexico 2019–2025 ($ million)

Exhibit 126          Market in Mexico 2019–2025 ($ million)

Exhibit 127          MEA HPV Testing Market 2019

Exhibit 128          MEA Market: Absolute & Incremental Growth

Exhibit 129          Middle East and North Africa Cervical Cancer Deaths

Exhibit 130          Market in MEA 2019–2025 ($ million)

Exhibit 131          MEA: Market by Product 2019−2025 ($ million)

Exhibit 132          MEA: Market by Product 2019−2025 (%)

Exhibit 133          Incremental Growth in MEA 2019-2025

Exhibit 134          Market in Turkey 2019–2025 ($ million)

Exhibit 135          Market in South Africa 2019–2025 ($ million)

Exhibit 136          Market in Saudi Arabia 2019–2025 ($ million)

Exhibit 137          Global HPV Testing Market Share: Vendors Share 2019

Exhibit 138          F. Hoffmann-La Roche: Revenue by Business Segments in 2017−2018 ($ billion)

Exhibit 139          F. Hoffmann-La Roche: R&D Expenditure in 2016−2018 ($ billion)

Exhibit 140          F. Hoffmann-La Roche: Revenue by Geography ($ billion)

Exhibit 141          QIAGEN: Revenue by Business Segments in 2017−2018 ($ million)

Exhibit 142          QIAGEN: R&D Expenditure in 2016−2018 ($ million)

Exhibit 143          QIAGEN: Revenue by Geography in 2018 ($ million)

Exhibit 144          Hologic: Revenue by Segments 2018−2019 ($ million)

Exhibit 145          Hologic: R&D Expenditure 2017−2019 ($ million)

Exhibit 146          Hologic: Revenue by Geography 2019 ($ million)

Exhibit 147          Abbott: Revenue by Segments 2017−2018 ($ million)

Exhibit 148          Abbott: R&D Expenditure 2016−2018 ($ million)

Exhibit 149          Abbott: Revenue by Geography ($ million)

               

List of Tables    

Table 1                  Key Caveats

Table 2                  Currency Conversion 2014−2019

Table 3                  High-risk HPV-induced Cancers

Table 4                  Major Vendors Offering HPV Testing Solutions

Table 5                  Market Penetration of Human Papillomavirus Test by Regions

Table 6                  Commercially Available POC HPV Products

Table 7                  Absolute Growth of Human Papillomavirus Testing in Developed and Emerging Economies (%)

Table 8                  Commercially Available mRNA Test

Table 9                  List of Key HPV Testing Instruments from Market Players

Table 10               Key HPV Diagnostic Analyzers Available in the Market

Table 11               Significant Players Offering Human Papillomavirus Testing Products for the Detection of Cervical Cancer

Table 12               Classification of Human Papillomavirus Associated Penile Carcinomas, Relative Frequency and Mean Cancer-Specific Mortality by WHO

Table 13               Healthcare Expenditure as Percent of GDP in Major Latin American Countries

Table 14               Global HPV Testing Market: Top Vendors Ranking

Table 15               F. Hoffmann-La Roche: Key Product Offerings

Table 16               QIAGEN: Key Product Offerings

Table 17               Hologic: Key Product Offerings

Table 18               Abbott: Key Product Offerings

Table 19               Arbor Vita: Key Product Offerings

Table 20               BD: Key Product Offerings

Table 21               Cepheid: Key Product Offerings

Table 22               DAAN Gene: Key Product Offerings

Table 23               DiaCarta: Key Product Offerings

Table 24               Fujirebio: Key Product Offerings

Table 25               Greiner Bio-One International: Key Product Offerings

Table 26               Hybribio: Key Product Offerings

Table 27               IncellDx: Key Product Offerings

Table 28               Norgen Biotek: Key Product Offerings

Table 29               PreTect: Key Product Offerings

Table 30               Seegene: Key Product Offerings

Table 31               Siemens Healthineers: Key Product Offerings

Table 32               Takara Bio: Key Product Offerings

Table 33               Xiamen Zeesan Biotech: Key Product Offerings

Table 34               ZYTOVISION: Key Product Offerings

Table 35               Global Human Papillomavirus Testing Market by Product ($ million)

Table 36               Market by Product (%)

Table 37               Market by Application ($ million)

Table 38               Market by Application (%)

Table 39               Market by End-users ($ million)

Table 40               Market by End-users (%)

Table 41               Market by Geography ($ million)

Table 42               Market by Geography (%)

Select a license type that suits your business needs

single-user Single User Licence
$3500.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$4000.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$5000.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date